Современная онкология (Nov 2021)
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
Abstract
The incidence of prostate cancer in the structure of malignant neoplasms occupies the fourth place, it is 7.3%. 1 414 259 new cases and 375 304 deaths were estimated worldwide in 2020. In recent decades, there was a significant increase in the number of cases of metastatic castration-resistant prostate cancer (mCRPC). There is no consensus on the optimal treatment choice, nowadays. The various therapeutic options are offered for these aims. But, the regimes and the consistence of their application are problematical and far from being resolved. The aim of this review is to analyze the studies on the use of cabazitaxel in the treatment of mCRPC. The history of the taxanes application in advanced and metastatic prostate cancer dates back to 2004, when the United States Food and Drug Administration registered docetaxel as first-line therapy for patients with metastatic prostate cancer. Cabazitaxel the new second generation taxane appeared in 2010, and showed the activity in the development of castration resistance. The drug demonstrated high antitumor activity and significant efficacy at the time of progression against the background of treatment with docetaxel and androgen receptor inhibitors. The results of the number of the randomized clinical trials associated with the various aspects of treatment tactics in mCRPC are available for the analysis, nowadays. However, these data and especially the clinical benefit are ambiguous, and sometimes contradictory. The review presents the results of the scientific researches, international clinical studies concerning the various aspects of mCRPC, in particular the choice of modern optimal treatment tactics.
Keywords
